Colombia v Novartis: Do Big Prices Mean More Compulsory Licensing?
Executive Summary
After making noise about issuing a compulsory license, Colombia is now moving to force Novartis AG to lower its price for Glivec. The news could signal that pharmaceutical companies with high-priced medicines will face increasing threats to their intellectual property if they continue to charge big prices that middle- income countries cannot afford.
You may also be interested in...
Colombian Crack Down On Compulsory Licensing Under Attack
Civil society groups are calling for Colombian authorities to repeal a controversial decree that they say will make compulsory licensing harder and which would prevent declarations of public interest from being used to lower drug prices.
Novartis Takes On Colombia Over Glivec Pricing
Novartis is taking Colombian authorities to court over moves to cut the price of its anticancer Glivec (imatinib) and warns that the intellectual property rights of other products are under threat. Companies selling hepatitis C drugs should pay attention as their products could be next to face similar measures.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.